Christian H Rickert1, Werner Paulus. 1. Institute of Pathology, University Hospital Münster, Domagkstrasse 17, 48149 Münster, Germany. rickchr@uni-muenster.de
Abstract
INTRODUCTION: Atypical teratoid/rhabdoid tumours (AT/RT) are highly malignant embryonal tumours of the brain composed of rhabdoid cells. Inactivating mutations of the hSNF5/INI-1 gene located in the chromosomal region 22q11.2 are regarded as a crucial step in their molecular pathogenesis. Apart from monosomy or deletions of chromosome 22 not much data exists on additional chromosomal aberrations. METHODS: We investigated seven primary AT/RT by comparative genomic hybridisation (CGH) and found DNA copy number changes in each case. RESULTS: These consisted of loss of 22q in 7 out of 7 (100%) and loss of 19 in 3 out of 7 (43%) patients. In 4/7 AT/RT (57%), loss of chromosome 22q was the sole aberration whereas one patient showed additional losses of 16p, 17p and 20q. CONCLUSIONS: Our CGH data suggest that apart from monosomy 22 additional genetic pathways may seem feasible for a subset of AT/RT that is yet to be defined. Furthermore, this study also emphasises the potential practical value of loss of chromosome 22 as a diagnostic marker for AT/RT. Copyright 2004 Springer-Verlag
INTRODUCTION: Atypical teratoid/rhabdoid tumours (AT/RT) are highly malignant embryonal tumours of the brain composed of rhabdoid cells. Inactivating mutations of the hSNF5/INI-1 gene located in the chromosomal region 22q11.2 are regarded as a crucial step in their molecular pathogenesis. Apart from monosomy or deletions of chromosome 22 not much data exists on additional chromosomal aberrations. METHODS: We investigated seven primary AT/RT by comparative genomic hybridisation (CGH) and found DNA copy number changes in each case. RESULTS: These consisted of loss of 22q in 7 out of 7 (100%) and loss of 19 in 3 out of 7 (43%) patients. In 4/7 AT/RT (57%), loss of chromosome 22q was the sole aberration whereas one patient showed additional losses of 16p, 17p and 20q. CONCLUSIONS: Our CGH data suggest that apart from monosomy 22 additional genetic pathways may seem feasible for a subset of AT/RT that is yet to be defined. Furthermore, this study also emphasises the potential practical value of loss of chromosome 22 as a diagnostic marker for AT/RT. Copyright 2004 Springer-Verlag
Authors: N Sévenet; A Lellouch-Tubiana; D Schofield; K Hoang-Xuan; M Gessler; D Birnbaum; C Jeanpierre; A Jouvet; O Delattre Journal: Hum Mol Genet Date: 1999-12 Impact factor: 6.150
Authors: S B Wharton; C Wardle; J W Ironside; W H Wallace; J A Royds; D W Hammond Journal: Neuropathol Appl Neurobiol Date: 2003-06 Impact factor: 8.090
Authors: George Toth; Claudia B Zraly; Tricia L Thomson; Carolyn Jones; Shawn Lapetino; Jonathan Muraskas; Jiwang Zhang; Andrew K Dingwall Journal: Genes Chromosomes Cancer Date: 2011-03-15 Impact factor: 5.006
Authors: Peter H O'Donnell; Ana Jensen; Edwin M Posadas; Julia A Bridge; Anjana V Yeldandi; Ximing J Yang; Walter M Stadler; Hikmat Al-Ahmadie Journal: Nat Rev Urol Date: 2010-02 Impact factor: 14.432
Authors: Robert G J Vries; Vladimir Bezrookove; Lobke M P Zuijderduijn; Sima Kheradmand Kia; Ada Houweling; Igor Oruetxebarria; Anton K Raap; C Peter Verrijzer Journal: Genes Dev Date: 2005-03-15 Impact factor: 11.361
Authors: Elizabeth S McKenna; Courtney G Sansam; Yoon-Jae Cho; Heidi Greulich; Julia A Evans; Christopher S Thom; Lisa A Moreau; Jaclyn A Biegel; Scott L Pomeroy; Charles W M Roberts Journal: Mol Cell Biol Date: 2008-08-18 Impact factor: 4.272